GET DAILY SIGNALSThermo Fisher Scientific (TMO): Why a $780 Analyst Target Suggests +12% Upside
Key Takeaways
- The central $780 stock price target represents the average of verified analyst targets above the current share price, not an official consensus. The broader average of all tracked targets (around $690–$750) sits at or only modestly above the current price, so the focus here is on the above-price subset.
- Thermo Fisher Scientific Inc. (TMO) closed at $694.76 on November 6, 2026, so reaching $780 would require an advance of about 12%.
- The full analyst target range remains wide, spanning roughly $520 to $830, which reflects real differences of opinion on the pace of recovery in life-science end markets.
- Strong Q3 2026 results, raised full-year guidance, and a series of post-earnings target increases form the main supporting factors.
- Key risks include a premium valuation, uneven pharma and biotech spending, flat academic and government demand, and resistance near the 52-week high.
- Additional detail is available on dedicated pages covering Major News, Today's Price Move, Forecast, and Earnings.
Analyst Price Targets and Consensus View
Thermo Fisher Scientific ranks among the largest providers of life-science tools and services, serving pharmaceutical, biotech, academic, and government customers. Coverage is extensive, yet views on valuation remain divided at present.
The overall average analyst price target falls in the $690–$750 range depending on the source—S&P Global’s 27-analyst average stands near $752, while other trackers show roughly $689–$696. Since those levels sit at or only modestly above the latest price, the $780 central target used here is simply the arithmetic mean of the most recent individual targets that exceed the current share price.
Nine above-price targets produce the $780 figure: J.P. Morgan at $820 and Citi at $800 (both October 23), DZ Bank at $800 (October 22), Bank of America at $795 and Argus Research at $780 (both October 30), Barclays at $775 (November 2), Stifel at $775 and Baird at $756 (October 22), and Morgan Stanley at $730 (October 13). The rounded mean comes to about $781, or $780 when rounded.
The full range stretches much wider—from roughly $520 to $830—reflecting a combination of Strong Buy and Buy ratings alongside a smaller number of Hold and Sell calls. Bullish analysts highlight recovering tools demand and the company’s scale, while more cautious voices note that the valuation already embeds much of the expected recovery.
Current Market Position and Path Toward the Target
At $694.76, the shares trade within about 2.4% of the 52-week high of $712.17 and roughly 60% above the 52-week low of $435.27. Reaching $780 implies a modest advance of approximately 12%—meaningful for a large-cap stock near a record, yet far less dramatic than the re-ratings some growth names require.
The path forward likely hinges on sustained earnings delivery rather than multiple expansion. TMO carries a P/E around 36x trailing earnings, so meaningful upside would need to come from higher EPS and continued organic revenue growth. After a strong October earnings report that beat expectations and lifted full-year guidance, the near-term catalyst picture looks constructive, though the stock has already moved higher quickly.
What Could Support a Move Toward the Target
- Resilient demand across pharma, biotech, and bioproduction, along with momentum in analytical instruments and AI-related laboratory demand.
- Raised full-year revenue, EPS, and free-cash-flow guidance following the Q3 2026 report.
- A wave of post-earnings price-target increases from J.P. Morgan, Citi, Bank of America, Barclays, Stifel, and others.
- Thermo Fisher’s one-stop-shop scale and diversified end markets, which analysts view as a durability advantage over smaller peers.
What Could Prevent the Target From Being Reached
- Valuation compression: at roughly 36x trailing earnings, any earnings or sentiment stumble could pressure the multiple.
- Flat academic and government revenue and muted reagent demand, areas management itself highlighted as softer.
- Uneven pharma services timing and cautious customer capital-spending decisions.
- Resistance near the $712 record high—a level that has already capped several rallies.
Technical Levels and Market Structure
The $712.17 52-week high stands as the clearest overhead resistance level, with the round-number $700 mark serving as a secondary psychological barrier. On the downside, the November 6 intraday low of $661.60 and the $676 area mark near-term support. A decisive, sustained close above $712 would signal a breakout, while failure to hold the mid-$660s would suggest the rally is consolidating. The longer-term trend remains firmly upward after the stock recovered from its May 2026 lows.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary and none offers a firm timing guarantee. Investors should watch quarterly earnings—the next report is estimated for late January 2027—updates to full-year guidance, further analyst target revisions, and any signals on academic, government, and biotech spending. Interest-rate decisions and sector rotation into or out of defensive health-care names also matter for a premium-multiple stock.
Using Tickeron’s AI Daily Buy/Sell Signals for Monitoring
I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry. The tool applies artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, keep tabs on existing positions, and spot shifting trends more efficiently than manual screening alone. If you want a data-driven second opinion on names like TMO, the AI Daily Buy/Sell Signals tool is a practical place to start.
Final Assessment
The $780 target is a calculated average of the analyst price targets that remain above the current share price, representing roughly 12% upside from $694.76. Support rests on strengthening demand, raised guidance, and a favorable post-earnings revision cycle, while the principal obstacles are a rich valuation, selective end-market softness, and resistance at the $712 record high. With a target range spanning about $520 to $830, analyst disagreement is unusually wide—making upcoming earnings, guidance, and revisions the most important things to monitor rather than any single price level.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 56 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 146 of 247 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 66 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 59%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 25 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.876) is normal, around the industry mean (67.298). P/E Ratio (37.333) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of analytical and environment monitoring instruments
Industry MedicalSpecialties
Advertisement